Additionally, delgocitinib inhibits IL-31-induced pruritus, contributing to symptom relief [13]. In this case, dupilumab administration effectively suppressed the inflammatory cytokines involved in pruritus (IL-4 and IL-13), resulting in well-controlled trunk lesions. Here, IL13 is linked to Pruritus.